Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
NGO

Institute for Follicular Lymphoma Innovation

Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 08, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Tech
PeproMene Bio announced the publication in The Lancet of results from its Phase 1 clinical trial of PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial…
Impact: IFLI provided up to $11 million in funding to support the clinical development of PMB-CT01. The positive results validate its investment and support its mission to advance treatments for follicular lymphoma.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Institute for Follicular Lymphoma Innovation live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.